Attovia Therapeutics, Inc. ATTO
15.53 USD +0.67 (+4.51%)
Regular-session close
15.53 0.00 0.00%
After hours · Nov 18, 4:00 PM ET
14.30 Day range 16.35
12.94 52-week range 28.00
- YTD
- -29.09%
- 1 year
- -29.09%
News
benzinga.com Citigroup Maintains Buy on Attovia Therapeutics, Raises Price Target to $34 Citigroup analyst Yigal Nochomovitz maintains Attovia Therapeutics (NASDAQ:ATTO) with a Buy and raises the price target from $30 to $34.
benzinga.com Morgan Stanley Maintains Overweight on Attovia Therapeutics, Raises Price Target to $40 Morgan Stanley analyst Judah Frommer maintains Attovia Therapeutics (NASDAQ:ATTO) with a Overweight and raises the price target from $39 to $40.
seekingalpha.com Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcriptbenzinga.com Attovia Therapeutics Q3 EPS $(0.76) Misses $(0.50) Estimate Attovia Therapeutics (NASDAQ:ATTO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.50) by 52 percent. This is a 77.91 percent increase over losses of…
globenewswire.com Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase 2 trials of ATTO-1310 in…
marketbeat.com Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials Attovia Therapeutics NASDAQ: ATTO reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with…
globenewswire.com Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis Results build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic…
globenewswire.com Attovia Therapeutics to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation…
globenewswire.com Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for…
seekingalpha.com Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Attovia Therapeutics to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation…
globenewswire.com Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026
247wallst.com Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that…
247wallst.com Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology…
defenseworld.net Attovia Therapeutics (NASDAQ:ATTO) Director Acquires $1,785,000.00 in Stock Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) Director Colin Walsh purchased 85,000 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was bought at an…
defenseworld.net Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Global Strategic Fund Venbio Purchases 382,352 Shares of Stock Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) major shareholder Global Strategic Fund Venbio purchased 382,352 shares of the business's stock in a transaction that occurred on Thursday,…
defenseworld.net Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Redmile Group, Llc Purchases 200,000 Shares Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) major shareholder Redmile Group, Llc bought 200,000 shares of Attovia Therapeutics stock in a transaction on Thursday, August 6th. The…
globenewswire.com Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for…
prnewswire.com Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5,…
globenewswire.com Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for…
globenewswire.com Attovia Therapeutics Appoints John W. Smither to Board of Directors Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector Mr. Smither brings extensive public company board and audit committee experience in the…
